*ANTISOMA* wird NICHT abschmieren !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! - 500 Beiträge pro Seite

[david1]

Die Antisoma wird nicht abschmieren.
Warum auch, nur weil " Der Aktionär " Empfehlung ausgesprochen hat?????????
Das ist ja Kindergarten Logik !!!!!!!!!!

Gestern sind die super News aus England gekommen, und nicht von Förtsch.

Gruß david1

[bernie55]

Kann die Hysterie auch nicht verstehen...
Habe heute nochmal bei 4,15 Euro eine kleine Schippe nachgelegt...
Also, ruhig Blut, keine Panik, in einigen Wochen... Monaten... Jahren werdet ihr euch an Antisoma erfreuen
mfg bernie

[gholzbauer]

Nachkaufgelegenheit, je tiefer, desto besser.

[Joronin]

@ gholzhauer

Damals haben sicher auch die ersten so am 5. März nachgekauft.

Grußk,
joronin

[frey-pop]

Ist schon am abschmieren.

[gholzbauer]

Naja, ich meine nicht bei jetzt 4,2 Euro nachkaufen, sondern wenn
`s in der Panik Richtung 2,5 oder drunter geht.

Man sollte die "Fakten" unabhängig von Förtsch & Co nicht vergessen:




Potential market [ for Theragyn ]


Latest worldwide figures estimate that ovarian cancer is the second most common gynaecological cancer, after that of the uterine cervix. In the US, it is the fifth most common cause of cancer death in women, after cancers of the lung, breast, large bowel and pancreas.


The prognosis depends on how early the cancer is detected. Five-year survival is much higher when treatment begins at an early stage, before the disease has spread.

Unfortunately, in practice, early diagnosis is difficult, because the ovaries sit deep inthe abdomen, and overall survival rates are much lower.


Surgical removal of the primary cancer and chemotherapy enables many patients to achieve remission, but in most cases this is followed by relapse, and the cycle of treatment, remission, relapse can repeat itself several times until the patient finally succumbs.


An ICRF Phase II clinical trial identified women in remission as being an initial target for treatment. Antisoma estimates that about 65% of new cases and 20% of relapsed case could be treated with Theragyn in these key markets. This gives a potential market size of 85,000 patients per annum in North America, Europe and Japan (based on 1995 data). At a predicted selling price of US$10,000 per treatment, the market for Theragyn is potentially worth US$850 million per annum.



Orphan Drug Designation


In March 1999, the US Food and Drugs Administration (FDA) granted Orphan Drug Designation to Theragyn for adjuvant treatment of ovarian cancer.


This means that Theragyn will enjoy a 7-year period of market exclusivity if the drug is approved for marketing in the US.


The US Orphan Drug Act was designed to encourage the development of treatments for conditions that affect less than 200,000 people in the US. Similar legislation is in force in Japan and Australia, and is expected in the EU in 2001 although it is not, at this time, certain whether Theragyn would be eligible, particularly in Europe where the threshold is set lower than in the US. Even so, under existing regulations, we would still have 10 years exclusive use of the Theragyn data package once approval is received in Europe.

[gholzbauer]

für die schwachen Hände gilt natürlich weiterhin:

PANIK!!!!